Hyponatremia and V2 vasopressin receptor upregulation: a result of HSP90 inhibition

PURPOSE: Small-molecule inhibitors of heat-shock protein 90 (HSP90) have been under development as chemotherapeutic agents. The adverse events reported from early clinical trials included hyponatremia. Given the limited number of patients enrolled, the number of hyponatremia incidents was remarkable...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Qiong, Puhm, Florian, Freissmuth, Michael, Nanoff, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5608778/
https://www.ncbi.nlm.nih.gov/pubmed/28779264
http://dx.doi.org/10.1007/s00280-017-3390-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5608778/
https://www.ncbi.nlm.nih.gov/pubmed/28779264
http://dx.doi.org/10.1007/s00280-017-3390-x

Ejemplares similares